You are invited to join us February 12-14, 2017 in Washington D.C. for what is going to be another critical year in Duchenne advocacy.

2016 marked a tremendous victory in our collective history, the first FDA approval of a Duchenne therapy – Exondys 51. It is important to remember that you, our advocacy community, paved the road to this approval. Beginning with the passage of the MD-CARE Act in 2001 followed by the reauthorization in 2008 and the Amendment in 2014, this community helped to carve a path for care improvements, research innovation, and drug development by enabling a public private partnership in Duchenne.

Every year, over 150 Duchenne advocates come to Washington in February to urge Congress to continue to make Duchenne a priority at the following agencies:

• Center for Disease Control (CDC)
• National Institutes of Health (NIH)
• Department of Defense (DOD)
• Food and Drug Administration (FDA)

We MUST keep Duchenne on the front lines of agency priorities and maintain our growing presence in DC.

Please Consider Joining us February 12-14, 2017

No matter what happens on Election Day, we will have a new President and Congress. It is imperative we come together as a united Duchenne community in February to establish new relationships with new leadership in order to expand the number of congressional champions who consider Duchenne among their top priorities. Your presence in D.C. this February is a critical part of the Duchenne community’s strength and impact going forward.

Basic Agenda

• Sunday, February 12th, 3pm-7:30pm - Advocate training
• Monday, February 13th, 9am-12pm - Access & Reimbursement Policy Forum
• Monday, February 13th, 9am-5pm - Hill meetings
• Tuesday, February 14th, 9am-5pm - Hill meetings

First Time Advocating?

Don't be intimidated. Before you meet with your members of Congress, PPMD will provide you with extensive training and support, so you go into your meetings feeling empowered and prepared.

We hope to see you all in D.C.!

Let me know if you have any questions.